Improving Quality of Care and Patient Outcomes in Overactive Bladder: A Managed Care Approach to Management
This activity is jointly provided by Postgraduate Institute for Medicine and Talem MedEd.
Supported by an educational grant from Urovant Sciences.
September 15, 2022
September 15, 2023
TIME TO COMPLETE ACTIVITY
Overactive bladder (OAB) is a chronic condition characterized by urinary urgency that impacts up to 17% of the US population, with prevalence increasing with age. Since OAB has significant effects on clinical, economic, and quality of life outcomes, it is important for pharmacists—particularly those in the managed care setting—to understand best practices for treatment and individualized management. In this activity, expert faculty will review the safety and efficacy of available treatment options for OAB as well as current evidence, guidelines, and payer benefit management strategies to ensure appropriate access to and utilization of therapy. Insights on how to improve patient safety and clinical outcomes for patients with OAB will also be discussed.
This activity is designed specifically for pharmacists practicing in managed care settings.
Upon completion of this program, participants should be better able to:
- Evaluate the clinical and economic impact of OAB
- Analyze the safety and efficacy of available treatment options for OAB, including antimuscarinics and beta-3 adrenoceptor agonists
- Integrate novel therapies for OAB into treatment algorithms and utilization management strategies, considering key recommendations and recent evidence
- Discuss strategies for improving patient safety and clinical outcomes in OAB
Benjamin M. Brucker, MD
Division Director, Female Pelvic Medicine and Reconstructive Surgery and Neurourology
Associate Professor, Departments of Urology and Obstetrics and Gynecology
NYU Langone Health
New York, NY
Michael R. Stinchon, Jr., RPh
Associate Director, Formulary and Trend
JOINT ACCREDITATION STATEMENT
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Talem MedEd. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
CONTINUING PHARMACY EDUCATION
Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number – JA4008162-9999-22-347-H01-P)
Type of Activity: Application
HOW TO OBTAIN CREDIT
This activity is offered at no cost to participants. To receive CE credit participants must:
- Read the CME/CE information, including learning objectives and disclosure statements.
- Complete the pre-test.
- View the educational activity.
- Complete the post-test and evaluation form directly after the activity within a maximum of 60 days of participating in the activity. Once completed, click on the Grade Exam button at the bottom of the page. Your post-test will automatically be graded. If you successfully complete the post-test (score of 75% or higher), your statement of participation will be made available immediately. Click on the View Statement of Participation link and print the statement for your records.
If you receive a score lower than 75%, you will receive a message notifying you that you did not pass the post-test. You will have unlimited opportunities to pass the post-test. To receive Credit, you must provide your date of birth and NABP number. All Credit information will be uploaded into CPE monitor within 30 days.
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine and Talem MedEd adhere to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Postgraduate Institute for Medicine requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies (commercial interests). All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to Postgraduate Institute for Medicine policy. Postgraduate Institute for Medicine is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:
Benjamin M. Brucker, MD, disclosed the following relevant financial relationships: grant/research support from Allergan and Boston Scientific; speakers’ bureau/honoraria and consultant/advisory board member for Allergan, Anteres Pharma, Inc., and Urovant Sciences; and stock ownership in Watkins-Conti Products, Inc.
Michael R. Stinchon, Jr., RPh, has no relevant financial relationships to disclose.
Planners, Managers, and Reviewer
The Postgraduate Institute for Medicine and Talem MedEd planners, managers, and reviewer have nothing to disclose.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
There is no fee for this educational activity.
For general information or questions about this activity, please contact Talem MedEd at 800-913-9370 or email@example.com.
For questions regarding the certification of this activity, please contact Postgraduate Institute for Medicine at firstname.lastname@example.org.
©Talem MedEd, a division of Talem Health, LLC 2022. All Rights Reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Talem Health, LLC is prohibited.